Cigna's Evernorth business caps GLP-1 drug copays at $200 or less, aiming to boost affordability for patients and cut costs for health plan sponsors.

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

For a limited time, Wegovy will be available to new patients at $199 for the first month, Novo Nordisk said Thursday.

Hims & Hers stock took a nosedive after Cigna’s Evernorth division announced a $200 monthly cap on popular weight-loss drugs ...

Evernorth has capped antiobesity drug monthly co-pays at $200 in a move to improve access and affordability amid new drug ...

Investing.com -- Cigna’s Evernorth has introduced a new pharmacy benefit that caps out-of-pocket costs for GLP-1 weight loss ...

Shares of telehealth provider Hims & Hers Health Inc. (HIMS) dropped over 3% on Thursday after Cigna Group’s (CI) Evernorth ...

Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.

Analysts at Citi and Bank of America (NYSE:BAC) are maintaining a cautious stance on Hims & Hers Health as competition in the GLP-1 space intensifies and growth begins to moderate.

Only half of health insurer Cigna’s (NYSE:CI) clients currently cover the popular GLP-1 weight loss drugs Wegovy and Zepbound because of their high costs. But the company’s pharmacy benefits unit ...

An investigation by The Guardian finds the insurance giant UnitedHealth Group quietly paid thousands in bonuses to nursing home facilities that helped it gain Medicare enrollees and reduce ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...